Why the study?
Do metabolic modulators, particularly trimetazidine, improve outcomes when added to conventional medical therapy in patients with heart failure?
Do metabolic modulators, particularly trimetazidine, improve outcomes when added to conventional medical therapy in patients with heart failure?
Modulating cardiac energy metabolism with agents like trimetazidine represents a promising adjunctive approach to conventional medical therapy in heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for metabolic modulation in HF; should not yet change clinical practice.
Metabolic impairments play an important role in the development and progression of heart failure. The use of metabolic modulators, the number of which is steadily increasing, may be particularly effective in the treatment of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. This review focuses on the role of metabolic modulators, in particular trimetazidine, as a potential additional medication to conventional medical therapy in heart failure.
No takes yet. Share an insight, caveat, or question.
A 2015 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: